← Leaderboards
Alice Soragni
University Of California Los Angeles
$5,233,652
Attributed
$8,516,971
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,516,971 · 3
By mechanism
R01$8,516,971 · 3
Top collaborators
- Patricia Leal Dahia10 shared
- Paul Christopher Boutros8 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Utpal Banerjee$21,280,716
- Faith Lauren Hall-Glenn$33,571
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorOrganoidsChemotherapyMolecularMalignant NeoplasmsPharmaceutical PreparationsSurvival RateDiagnosisNeoplasm MetastasisClinical TrialsBiological ModelsDrug SensitivityMutationDesignDrug ScreeningWhole GenomeBehaviorCellsFuturePrimary NeoplasmTumor ProgressionResistanceSamplingSpecimen
Grant awards (25)
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$497,187
R01 · FY2025 · CA
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$237,198
R01 · FY2025 · CA
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$74,115
R01 · FY2025 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$472,053
R01 · FY2024 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$468,662
R01 · FY2024 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$318,066
R01 · FY2024 · CA · contact PI
Evaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid models$265,946
R01 · FY2024 · CA
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$70,409
R01 · FY2024 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$486,959
R01 · FY2023 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$483,461
R01 · FY2023 · CA
Targeting p53 conformational defects to arrest carcinogenesis$349,713
R01 · FY2023 · CA · contact PI
The Evolution of Sarcoma Drug Sensitivity through Time and Space$334,806
R01 · FY2023 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$74,115
R01 · FY2023 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$486,959
R01 · FY2022 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$483,461
R01 · FY2022 · CA
Targeting p53 conformational defects to arrest carcinogenesis$356,850
R01 · FY2022 · CA · contact PI
Signaling Drivers of Sarcoma Drug Resistance$334,806
R01 · FY2022 · CA · contact PI
Targeting p53 conformational defects to arrest carcinogenesis$90,104
R01 · FY2022 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$525,382
R01 · FY2021 · CA
The Evolution of Sarcoma Drug Sensitivity through Time and Space$496,897
R01 · FY2021 · CA · contact PI
Targeting p53 conformational defects to arrest carcinogenesis$356,850
R01 · FY2021 · CA · contact PI
Targeting p53 conformational defects to arrest carcinogenesis$83,115
R01 · FY2021 · CA · contact PI
The Evolution of Sarcoma Drug Sensitivity through Time and Space$456,157
R01 · FY2020 · CA · contact PI
Targeting p53 conformational defects to arrest carcinogenesis$356,850
R01 · FY2020 · CA · contact PI
Targeting p53 conformational defects to arrest carcinogenesis$356,850
R01 · FY2019 · CA · contact PI